• Home
  • About Us
    • About Us
    • Leadership Team
  • Science
    • Biologics
    • Biomanufacturing
    • Pipeline
  • Investors
    • Overview
    • SEC Filings
    • Press Releases
    • Presentations
    • Corporate Governance
    • Investor Resources
      semaglutide
      • Email Alerts
      • FAQs
      • Tax Documents
  • Careers
  • Contact Us

Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout

Nov 19, 2026 | Press Releases

Strengthens scientific, regulatory, and government partnership capabilities Dr. Balboni will advise on Valion Bio’s scientific strategy to advance medical countermeasures and pursue government and industry partnerships SAN ANTONIO, TX / ACCESS Newswire /...

Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study

Nov 17, 2026 | Press Releases

Production run achieved approximately 27% higher productivity compared with historical manufacturing data while meeting all predefined drug substance acceptance criteria SAN ANTONIO, TX / ACCESS Newswire / November 17, 2026 / Valion Bio, Inc. (NASDAQ:VBIO)...

Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird’s National Security Conference

Nov 11, 2026 | Press Releases

Top-line results from fully NIAID-funded Entolimod efficacy study expected in early December SAN ANTONIO, TX / ACCESS Newswire / November 11, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) (“Valion” or the “Company”), a clinical-stage biopharmaceutical...

Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results

Oct 30, 2026 | Press Releases

NIAID-RNCP elects to evaluate the efficacy of Entolimod on gastrointestinal acute radiation syndrome (“GI-ARS”), after the announcement of positive safety findingsFully funded study will evaluate Entolimod’s potential to improve survival rates and...

Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation

Oct 28, 2026 | Press Releases

AFRRI study found no evidence of treatment-related toxicity following a single dose of Entolimod, supporting advancement toward a planned, fully funded therapeutic study evaluating survival and gastrointestinal recovery following radiation exposure SAN ANTONIO, TX /...

Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options

Oct 26, 2026 | Press Releases

Unsolicited Interest Reinforces Velocity’s Strategic Value as Valion Bio Evaluates Opportunities to Advance Entolimod SAN ANTONIO, TX / ACCESS Newswire / October 26, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) (“Valion” or the “Company”), a...
« Older Entries

Recent Posts

  • Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
  • Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
  • Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird’s National Security Conference
  • Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
  • Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation

Recent Comments

No comments to show.
©2026 Valion Bio

Privacy Policy

For ClearUP customer questions regarding warranty or other device inquiries, please reach out to customerservice@tivichealth.com.